泛素特异性肽酶10(USP10)通过Sirt6抑制肝脏脂肪变性、胰岛素抵抗和炎症
研究检测非酒精性脂肪性肝病(NAFLD)患者、高脂饮食(HFD)诱导肥胖小鼠、遗传性肥胖(ob/ob)小鼠及棕榈酸处理肝细胞中USP10表达,并用肝细胞特异性USP10缺失或过表达小鼠研究其功能与机制。USP10在脂肪肝中表达显著降低,缺失加重HFD所致代谢紊乱,过表达则抑制代谢紊乱及ob/ob小鼠NAFLD进展;机制为USP10与Sirt6相互作用并抑制其泛素化降解。结论:USP10通过Sirt6抑制肝脏脂肪变性、胰岛素抵抗和炎症。
要点
- NAFLD患者脂肪肝、肥胖小鼠及棕榈酸处理肝细胞中USP10表达显著降低。
- 肝细胞特异性USP10缺失加重12周HFD诱导的代谢功能障碍。
- USP10过表达抑制HFD小鼠代谢紊乱及ob/ob小鼠NAFLD发生,机制涉及与Sirt6相互作用并抑制其泛素化降解。
核心结论
- USP10通过Sirt6抑制肝脏脂肪变性、胰岛素抵抗和炎症。
研究设计与样本
- 检测NAFLD患者肝脏、HFD诱导肥胖小鼠、ob/ob小鼠及棕榈酸诱导肝细胞中USP10表达。
- 利用肝细胞特异性USP10缺失或过表达小鼠,经HFD处理或遗传缺陷诱导,研究USP10在肝脏脂肪变性、胰岛素抵抗和炎症中的作用。
- 在HFD处理小鼠中进一步研究USP10调控肝脏脂肪变性的分子机制。
主要发现
- USP10在NAFLD患者脂肪肝、肥胖小鼠及棕榈酸处理肝细胞中表达显著降低。
- USP10缺失加重12周HFD处理诱导的代谢功能障碍。
- USP10过表达显著抑制HFD处理后小鼠的代谢功能障碍,并抑制ob/ob小鼠NAFLD的发生。
- USP10通过与被Sirt6相互作用并抑制其泛素化和降解来调控肝脏脂肪变性。
- Sirt6过表达显著改善USP10缺失对肝脏脂肪变性、胰岛素抵抗和炎症的影响;Sirt6缺失降低USP10过表达对HFD处理的改善作用。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Nonalcoholic fatty liver disease (NAFLD) is characterized by hepatic steatosis, insulin resistance and inflammation, and the pathogenic mechanism of NAFLD is poorly understood. Ubiquitin-specific peptidase 10 (USP10), a member of the ubiquitin-specific protease family, is involved in environmental stress responses, tumor growth, inflammation, and cellular metabolism. However, the role of USP10 in hepatic steatosis, insulin resistance, and inflammation remains largely unexplored. USP10 expression was detected in livers of patients with NAFLD, mice with high-fat diet (HFD)-induced obesity, and genetically obese (ob/ob) mice, as well as in palmitate-induced hepatocytes. The function of USP10 in hepatic steatosis, insulin resistance, and inflammation was investigated using hepatocyte-specific USP10 deficiency or overexpression in mice induced by HFD treatment or genetic defect. The molecular mechanisms underlying USP10-regulated hepatic steatosis were further investigated in HFD-treated mice. USP10 expression was significantly decreased in the fatty livers of NAFLD patients and obese mice and in palmitate-treated hepatocytes. USP10 deficiency exacerbated the metabolic dysfunction induced by HFD treatment for 12 weeks. Conversely, USP10 overexpression significantly suppressed metabolic dysfunction in mice after HFD treatment and inhibited the development of NAFLD in ob/ob mice. Further investigation indicated that USP10 regulates hepatic steatosis by interacting with Sirt6 and inhibiting its ubiquitination and degradation. Sirt6 overexpression markedly ameliorated the effects of USP10 deficiency in hepatic steatosis, insulin resistance, and inflammation. Conversely, Sirt6 deficiency decreased the ameliorative effects of USP10 overexpression in response to HFD treatment. Conclusion: USP10 inhibits hepatic steatosis, insulin resistance, and inflammation through Sirt6.
引用
- Luo P, Qin C, Zhu L, et al. Ubiquitin-Specific Peptidase 10 (USP10) Inhibits Hepatic Steatosis, Insulin Resistance, and Inflammation Through Sirt6. Hepatology. 2018. PMID: 29698567. doi:10.1002/hep.30062
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。